AbCellera Biologics Inc. (ABCL) News
Follow AbCellera Biologics Inc. (ABCL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 19 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
AbCellera Q3 Revenue Beats Analyst Estimates
EQUITY | Nov 09, 2026, 09:17 PM UTC
M
AbCellera Reports Q3 2026 Business Results
AbCellera announced financial results for the third quarter of 2026.
EQUITY | Nov 09, 2026, 09:05 PM UTC
M
AbCellera Q3'26 Earnings Preview
AbCellera is scheduled to report Q3'26 results on November 9 after the market close. Revenue and EPS estimates were provided.
EQUITY | Nov 02, 2026, 12:01 PM UTC
L
Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?
Iovance Biotherapeutics (IOVA), AbCellera Biologics (ABCL) and CrowdStrike Holdings (CRWD) hit fresh 52-week highs on Tuesday as investors responded to stronger business outlooks, analyst support and AI-driven cybersecur
EQUITY | Sep 30, 2026, 02:57 AM UTC
L
AbCellera Biologics Initiated at Overweight by JP Morgan
Ratings actions from Benzinga: GMT) AbCellera Biologics Price Target Announced at $17.00/Share by JP MorganRatings actions from Benzinga
NEWS | Sep 29, 2026, 01:25 PM UTC
L
AbCellera Biologics Price Target Announced at $13.00/Share by Goldman Sachs
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 12:12 PM UTC
L
AbCellera to present at Cantor Global Healthcare Conference Sept. 9, 2026
AbCellera said it will present at the Cantor Global Healthcare Conference on September 9, 2026. A live audio webcast and later replay will be available via a link posted on its Investor Relations website.
EQUITY | Sep 02, 2026, 08:05 PM UTC
L
AbCellera rises as FDA approves Jazz Ziihera regimens
AbCellera Biologics shares trade higher on Tuesday as investors react to FDA approval of Jazz Pharmaceuticals’ two Ziihera-containing first-line regimens, with no company-specific catalyst supplied.
GEOPOLITICS | Aug 25, 2026, 06:38 PM UTC
L
AbCellera director Montalbano files Form 4P showing 10,000 shares bought
AbCellera Biologics Inc. director John S. P. Montalbano files a Form 4P reporting a 10,000-share transaction at $11.03 for $110,300.
REGULATION | Aug 18, 2026, 06:46 PM UTC
L
AbCellera CFO AndrewP Booth files Form 4
AbCellera Biologics Inc. reports a Form 4P filing by Chief Financial Officer AndrewP Booth showing 37,200 shares reported at $10.32 for $383,904.
REGULATION | Aug 14, 2026, 04:16 PM UTC
M
ABCL prices $200M offering at $9.75 per share
ABCL priced a $200M offering at $9.75 per share, according to TradeXchange Newsdesk.
EQUITY | Aug 13, 2026, 10:02 AM UTC
M
Multiple Companies Announce Public Offerings
Several companies announce public offerings and private placements of various securities
EQUITY | Aug 12, 2026, 09:25 AM UTC
M
ABCL Launches $200M Common Stock Offering
ABCL is offering $200M in common stock
EQUITY | Aug 11, 2026, 08:03 PM UTC
L
AbCellera Biologics Commences Underwritten Public Offering Of $200M Of Its Common Shares
AbCellera Biologics Inc. (NASDAQ: ABCL ) ("AbCellera") today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to certain investors, pre-
EQUITY | Aug 11, 2026, 08:03 PM UTC
M
ABCL Proposes Public Offering
ABCL announces proposed public offering of common stock and pre-funded warrants
EQUITY | Aug 11, 2026, 08:03 PM UTC
M
AbCellera Proposes Public Offering
AbCellera announces proposed public offering of common stock and pre-funded warrants
EQUITY | Aug 11, 2026, 08:01 PM UTC
L
Truist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30
Truist Securities analyst Robyn Kamaus maintains AbCellera Biologics (NASDAQ: ABCL ) with a Buy and raises the price target from $12 to $30.
EQUITY | Aug 11, 2026, 05:30 PM UTC
H
AbCellera Biologics call volume above normal and directionally bullish
Bullish option flow detected in AbCellera Biologics with 3,839 calls trading, 1.1x expected, and implied vol increasing over 2 points to 114.14%. Jul-26 7 calls and Jul-26 9 calls are the most active options, with total
EARNINGS | Jul 09, 2026, 04:05 PM UTC